HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study.

AbstractBACKGROUND:
Proteinuria in Heymann's nephritis, an experimental rat model disease corresponding to membranous nephropathy, has been shown to be due to lipid peroxidation. Since the pathophysiology might be similar to idiopathic membranous nephropathy in humans, we performed a prospective multicenter trial to investigate the efficacy of the lipid peroxidation scavenger, probucol.
METHODS:
Fifteen patients with biopsy-proven idiopathic membranous nephropathy resistant to conventional immunosuppressive therapy (n = 7) and/or ACEI treatment (n = 12) were recruited. Probucol (1 g/d orally) was administered for three months, followed by a washout period of four weeks, whereon lovastatin (10-20 mg/d orally) was administered for additional three months.
RESULTS:
A significant reduction in proteinuria was seen during the probucol treatment (median (range): 6.4 (3.8-9.1) g/d vs. 4.7 (1.3-16) g/d; P < 0.05), with partial remission achieved in four patients. Three of these patients had previously been resistant to immunosuppressive therapy. Median protein excretion increased to pretreatment values during the washout period (6.2 (1.9-15) g/d; P < 0.05) and was not significantly different after the intake of lovastatin (4.9 (1.8-19) g/d; P = NS). None of the patients achieved partial remission during lovastatin therapy (P < 0.05 vs. probucol).
CONCLUSION:
The present study led us to conclude that proteinuria can be reduced by probucol in some patients with idiopathic membranous nephropathy. A randomized multicenter study to further elucidate the influence of lipid peroxidation scavengers on membranous nephropathy is warranted.
AuthorsMartin Haas, Gert Mayer, Gerhard Wirnsberger, Herwig Holzer, Manfred Ratschek, Ullrich Neyer, Josef Neuweiler, Reinhard Kramar, Brigitte Schneider, Silvana Breiteneder-Geleff, Heinrich M Regele, Walter H Hörl, Dontscho Kerjaschki
JournalWiener klinische Wochenschrift (Wien Klin Wochenschr) Vol. 114 Issue 4 Pg. 143-7 (Feb 28 2002) ISSN: 0043-5325 [Print] Austria
PMID12060980 (Publication Type: Comparative Study, Journal Article, Multicenter Study)
Chemical References
  • Anticholesteremic Agents
  • Antioxidants
  • Lovastatin
  • Probucol
Topics
  • Adult
  • Anticholesteremic Agents (therapeutic use)
  • Antioxidants (adverse effects, therapeutic use)
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Glomerulonephritis, Membranous (drug therapy)
  • Humans
  • Kidney Function Tests
  • Lipid Peroxidation (drug effects)
  • Lovastatin (therapeutic use)
  • Male
  • Middle Aged
  • Probucol (therapeutic use)
  • Prospective Studies
  • Proteinuria (drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: